10 years of MetrioPharm – how was it for the team? We’re asking one of our very first employees. And our newest team member.
You are at a party: how do you explain what you do for a living?
Dr. Beate Ludescher: Difficult, this is a struggle I have at almost every party (laughs). Regulatory Affairs is everything that has to do with laws and guidelines. I therefore make sure that our drug – as far as it is within my power – clears all regulatory hurdles to approval. In addition, I have a few more jobs, we are still a small team. For example, I also work on our patents.
Dr. Sara Schumann: As a project manager for R&D, I mainly work in preclinical research. We are looking for new indications for our compound by planning trials with our partners. So, our question is very practical: What diseases could MP1032 be effective on?
Now MetrioPharm has just turned ten years old. Beate, what’s it like working on this project for so long?
Dr. Beate Ludescher: This is very exciting. Because we concentrate on one compound, we have an overall view of the entire process that takes place here. You experience the entire development phase of a drug.
Dr. Sara Schumann: I like that, too. I have just joined the team and I’m learning a lot. For example, I know all about what Beate is doing. Even if I don’t understand everything (laughs). With many other companies, it would be harder to look beyond my own field of work.
Dr. Beate Ludescher: And that’s exactly how the team grows as a whole. In the beginning, we never thought we’d make it to clinical Phase I. And now we are already far beyond that.
Beate, as a long-standing employee, what was – in retrospect – the biggest milestone for you in these ten years?
Dr. Beate Ludescher: Clearly for me: First Patient, First Dose, when we first applied MP1032 in humans. And then such a great safety profile showed up, that was an unbeatable one.
What are your next projects this year?
Dr. Beate Ludescher: We will apply for two new patents and in the US, we’ll publish study results. Our February won’t be boring.
Dr. Sara Schumann: We are currently planning toxicological studies associated to our clinical trials. And probably, we won’t be able not to look into one or two new indications.
That sounds exciting. Can you tell what it is about?
Dr. Sara Schumann: I’m sorry. This really is exciting, but I definitely can’t say anything about it (laughs).
Dear Beate, dear Sara, thank you for the interview.